Molecular idetification of CBFΒ-MYH11 fusion transcripts in an AML M4Eo patient in the absence in inv16 or other abnormality by cytogenetic and FISH analyses - A rare occurence [4]

Leukemia

Volumn 17, Issue 9, 2003, Pages 1907-1910

  Ravandi, F ^a   Kadkol, S S ^a   Ridgeway, J ^a   Bruno, A ^a   Dodge, C ^a   Lindgren, V ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; CORE BINDING FACTOR BETA; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MYOSIN HEAVY CHAIN; UNCLASSIFIED DRUG; VALSPODAR; CBFBETA MYH11 FUSION PROTEIN; CBFBETA-MYH11 FUSION PROTEIN; ONCOPROTEIN; RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; CASE REPORT; CHROMOSOME 16; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 16; CLINICAL FEATURE; COMORBIDITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; KARYOTYPING; LABORATORY TEST; LETTER; LEUKEMIA REMISSION; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; CHROMOSOME BREAKAGE; GENE REARRANGEMENT; GENETIC VARIABILITY; GENETICS; MYELOMONOCYTIC LEUKEMIA; PROGNOSIS;

ADULT; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 16; DNA MUTATIONAL ANALYSIS; GENE REARRANGEMENT; HUMANS; INVERSION, CHROMOSOME; KARYOTYPING; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RNA, NEOPLASM; VARIATION (GENETICS);

EID: 0141502158     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403056     Document Type: Letter

References (11)

1. Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2001; 19: 2482-2492.
2. Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D et al. Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998; 103: 72-78.
3. Langabeer SE, Walker H, Gale RE, Wheatley K, Burnett AK, Goldstone AH et al. Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 736-739.
4. Ritter M, Thiede C, Schakel U, Schmidt M, Alpen B, Pascheberg U et al. Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. Br J Haematol 1997; 98: 969-972.
5. Rowe D, Cotterill SJ, Ross FM, Bunyan DJ, Vickers SJ, Bryon J et al. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol 2000; 111: 1051-1056.
6. Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F et al. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85: 1313-1322.
7. Mitterbauer M, Laczika K, Novak M, Mitterbauer G, Hilgarth B, Pirc-Danoewinata H et al. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study. Am J Clin Pathol 2000; 113: 406-410.
8. Grimwade D. Screening for core binding factor gene rearrangements in acute myeloid leukemia. Leukemia 2002; 16: 964-969.
9. van der Reijden BA, Lombardo M, Dauwerse HG, Giles RH, Muhlematter D, Bellomo MJ et al. RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts. Blood 1995; 86: 277-282.
10. Mancini M, Cedrone M, Diverio D, Emanuel B, Stul M, Vranckx H et al. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia 2000; 14: 364-368.
11. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia. 2002; 16: 1176-1181.